COVID-19 boosters offered to anyone ages 18 and older

Translate to Spanish or other 102 languages!

Image for illustration purposes.

Mega Doctor News

- Advertisement -

RIO GRANDE VALLEY, Texas – UT Health RGV is now offering COVID-19 boosters (Pfizer-BioNTech and Moderna) to anyone ages 18 and older.

All fully vaccinated people aged 18+ can get a booster at least 6 months after their second dose of Pfizer or Moderna or at least 2 months after initial dose of Johnson & Johnson.

Community members aged 5+ can get vaccinated at the following locations:

- Advertisement -

EDINBURG

Tuesday, Nov. 30, 1-6 p.m.

HARLINGEN

Wednesday, Dec. 1, 1-6 p.m.

- Advertisement -

MISSION

Wednesday, Dec. 1, 1-6 p.m.

  • V Express Care by UT Health RGV (at H-E-B plus!), located at 2409 East Expressway 83. (By appointment only – call for available dates and times at 956-296-2935.

FOR PARENTS AND GUARDIANS OF CHILDREN AGED 5-11

  • You willreceive a call from 1-833-888-2268 (1-833-UTVACN8 ) upon scheduling your child’s appointment. Please save this phone number . 
  • This lower-dose Pfizer vaccine is the only COVID-19 vaccine to be authorized and recommended for use in children aged 5-11 years and should be administered as a two-dose series, three weeks apart — just as it is for people aged 12 and up.
  • Appointments for patient’s second dose will be scheduled on-site. 
  • All children under age 18 must be accompanied by a parent or guardian.

To make an appointment, log onto uthealth.org/vaccine or call 1-833-UTRGVMD.  

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Expands Kidney Transplant Program with Transplant Nephrologist, Dr. Victor E. Prado

As part of its ongoing commitment to bringing world-class healthcare to the Rio Grande Valley, DHR Health is pleased to announce the addition of double board-certified transplant nephrologist, Dr. Victor E. Prado. Dr. Prado will provide care to patients at DHR Health’s Transplant Institute,

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.

DHR Health to Host 13th Annual Circle of Care Caregivers Conference

DHR Health Rehabilitation Hospital will host its 13th Annual Circle of Care Caregivers Conference on Saturday, November 7, 2026, at the Edinburg Conference Center at Renaissance, offering educational presentations and resources for individuals caring for family members and loved ones.

HHS Opens $1 Million Funding Opportunity to Strengthen Women’s Preventive Care

The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced a Notice of Funding Opportunity (NOFO) for the Women’s Initiative for Screening and Health (WISH) program.
- Advertisement -